Eterna Therapeutics Launches Research to Evaluate its Lead Induced Mesenchymal Stem Cell Therapy Candidate’s (ERNA-101) ...
CAMBRIDGE, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics (Nasdaq: ERNA) today announced it will investigate the ability of its lead iMSC-based cell therapy (ERNA-101) to induce and modulate antitumor immunity in ovarian cancer and breast …